Kyung Hee University Hospital www.kyuh.co.kr 대한소화기학회지 2005;45:181-188 3 세대 Anti-HCV ELISA 검사의 진단 양성예측도 및 예측 인자 - Anti-HCV ELISA sample/Cutoff 비의 임상 의의를.

Slides:



Advertisements
Similar presentations
6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.
Advertisements

Improved Reflexive Testing Algorithm for Hepatitis C Infection Using Signal-to-Cutoff Ratios of a Hepatitis C Virus Antibody Assay K.K.Y. Lai, M. Jin,
Hepatitis C virus seroprevalence in Russian Federation: results of population based study Preliminary report K.Kyuregyan, N.Soboleva, V.Kichatova, O.Isaeva,
Protein GP73 (GOLGI PROTEIN 73) A NEW NON-INVASIVE BIOMARKER FOR ASSESSING LIVER FIBROSIS AND RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA N.K. Gatselis,
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
Epidemiology of chronic liver disease in Sudanese children
Metabolic Factors / NAFLD on the Natural History of Chronic Hepatitis B or C in Asia Pei-Jer Chen National Taiwan University & Hospital.
Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.
This is the most comprehensive compilation of epidemiological information on Hepatitis C Graciously provided by the University Hepatitis Center (last updated.
HCV Diagnosis. Features of Hepatitis C Virus Infection Incubation periodAverage 6-7 weeks Range 2-26 weeks Acute illness (jaundice)Mild (
EPIDEMIOLOGICAL AND CLINICAL FEATURES OF LIVER CIRRHOSIS
Serum Levels of Glycosaminoglycans (GAGs) and Insulin Like Growth Factor-1 (IGF-1) as New Diagnostic Markers for Hepatocellular Carcinoma. Ahmad S. Ibrahim*,
Hepatocellular Carcinoma from the ACC to Med E Paul M. Johnson Department of Internal Medicine University of North Carolina Hospitals February 12, 2010.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.
Date of download: 6/1/2016 From: Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons Ann Intern Med. 2016;164(2): doi: /M
Mun Hyuk Seong,1 Ho Kil,1 Young Seok Kim,2 Si Hyun Bae,3 Youn Jae Lee,4 Han Chu Lee,5 Byung Hak Kang,6 and Sook-Hyang Jeong1* Clinical and Epidemiological.
Identification of Potential Risk Factors for Mother-to- Infant HCV Transmission Slideset on: Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal.
INTRODUCTION & OBJECTIVES Introduction: The carcinogenesis of hepatocellular carcinoma (HCC) is a multifactorial, multistep and complex process. Its prognosis.
GASTROENTEROLOGY 2010;138:493–502 심 재 준 월요 저널.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein,
Jung Min Lee, Sang Hoon Ahn, Hyon Suk Kim, Hana Park, Hye Young Chang, Do Young Kim, Seong Gyu Hwang, Kyu Sung Rim, Chae Yoon Chon, Kwang-Hyub Han, and.
HEPATOLOGY, Vol. 61, No. 6, Introduction At least 1 / 3 of liver cirrhosis (LC) Chronic hepatitis B (CHB) Significant proportion of CHB progress.
Kris V. Kowdley, Patricia Belt, Laura A. Wilson, Matthew M. Yeh, Brent A. Neuschwander-Tetri, Naga Chalasani, Arun J. Sanyal, and James E. Nelson ; for.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Volume 130, Issue 4, Pages (April 2006)
Screening Test Kit Name
No conflict of interest
Volume 138, Issue 1, Pages e1 (January 2010)
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.
Can Renal Mass Features on CT Predict Positive Margins?
Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing? Intervirology 2015;58: DOI: /
Presented By: Sally Saad Mandour Esawy
Chronic viral hepatitis type B with “ground glass” cells
Successful TACE for HCC
Case Definition: HEPATITIS C
Orthotopic liver transplant, recurrent non-alcoholic steatohepatitis
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Volume 137, Issue 5, Pages (November 2009)
AFP > 9000 without demonstrable HCC
Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma  Gia L. Tyson, Zhigang Duan, Jennifer R. Kramer,
HEPATOCELLULAR CARCINOMA (HCC) at
Evaluation of the Patient With HCV Infection
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Volume 153, Issue 4, Pages (October 2017)
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.
Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers  Hidenori Toyoda, Takashi Kumada, Yukio Osaki, Hiroko.
Recurrence-free survival
Volume 122, Issue 2, Pages (February 2002)
Volume 138, Issue 1, Pages e1 (January 2010)
Volume 130, Issue 4, Pages (April 2006)
Volume 146, Issue 5, Pages e1 (May 2014)
PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,
Volume 137, Issue 5, Pages (November 2009)
Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis  Jin Dong Kim, Jong Young Choi, Si Hyun.
Volume 123, Issue 4, Pages (October 2002)
Evolution of liver transplantation for hepatocellular carcinoma
Volume 116, Issue 3, Pages (March 1999)
Bile duct invasion itself can be the prognosis factor in early HCC
Couple therapy for depression –effectiveness monitoring
Hashem B. El-serag, Thomas Tran, James E. Everhart  Gastroenterology 
Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Gary L Grunkemeier, PhD, Ruyun Jin, MD  The Annals of Thoracic Surgery 
Presentation transcript:

Kyung Hee University Hospital 대한소화기학회지 2005;45: 세대 Anti-HCV ELISA 검사의 진단 양성예측도 및 예측 인자 - Anti-HCV ELISA sample/Cutoff 비의 임상 의의를 중심으로 - 김영기, 김병호, 진은선, 남기덕, 장재영, 김남훈, 이상길, 주광로, 동석호, 김효종, 장영운, 이정일, 장 린

Kyung Hee University Hospital Kyung Hee University Hospital Background  anti-HCV ELISA positive ; present or past infection, false positive…   serum ALT, anti-HCV ELISA sample to cut-off ratio (S/CO ratio), RIBA positive  3 세대 anti-HCV ELISA 양성 -> HCV RNA 검사  anti-HCV ELISA sample to cut-off ratio (S/CO ratio) 에 따른 양성 예측 도, 영향 인자

Kyung Hee University Hospital Kyung Hee University Hospital Method  1998 년 11 월 ~2002 년 1 월  190 명 후향 연구 -> RT-PCR 양성군 / 음성군  예측인자 - 과거력, 간기능 검사, B 형 간염 표지자,  -FP, LC or HCC  recombinant HCr43, c200, c100-3,NS5 항원 - 3 세대 ELISA  anti-HCV ELISA S/CO ≥ 1 이면 양성 - > HCV RNA RT-PCR ( 검출한계 1000copies/mL ) 진단 기준 LC ; pathology or imaging + portal HTN ( GE varix or PLT≤130K /mm 3 ) HCC–pathology, 2 imaging or 1 imaging +  -FP ≥400 ng/mL)  stastical analysis

Kyung Hee University Hospital Kyung Hee University Hospital Result Table 1. Comparison of Demographic Features in the 3 rd Generation Anti-HCV ELISA Positive Patients according to RT-PCR Result

Kyung Hee University Hospital Kyung Hee University Hospital Table 2. Comparison of the Laboratory Data in the 3 rd Generation Anti-HCV ELISA Positive Patients according to RT-PCR Result

Kyung Hee University Hospital Kyung Hee University Hospital Fig. 1. Positive predictability of HCV infection according to the 3 rd generation anti-HCV ELISA sample to cut- off (S/CO) ratio. The patients with anti-HCV ELISA S/CO ratio below 6 have a significantly lower positive predictability compared to those with S/CO ratio more than 6. The patients who had abnormal liver function tests, liver cirrhosis, or hepatocellular carcinoma show higher positive predictive values (black bar), compared to the patients without any evidence of abnormal liver function tests, liver cirrhosis, or hepatocellular carcinoma (gray bar). The white bar means the percentage of positive predictive values of the total subjects. 17.9% 58.3% 78.6% 60%

Kyung Hee University Hospital Kyung Hee University Hospital Fig. 2. Accumulated positive predictability of HCV infection according to the 3rd generation anti-HCV ELISA sample to cut-off (S/CO) ratio at each specific value. The patients with anti-HCV ELISA S/CO ratio more than 6 show 63% of positive predictability, which plateau even though the S/CO value gets higher. The solid line means the cases that had abnormal liver function tests, liver cirrhosis, or hepatocellular carcinoma. The broken line means the cases with normal liver function tests that did not have liver cirrhosis or hepatocellular carcinoma.

Kyung Hee University Hospital Kyung Hee University Hospital Table 3. Univariate Analysis of Potential Risks for RT-PCR Positivity in the 3rd Generation Anti-HCV ELISA Positive Patients

Kyung Hee University Hospital Kyung Hee University Hospital Table 4. Univariate analysis of Laboratory Data for RT-PCR Positivity in the 3rd Generation Anti- HCV ELISA Positive Patients

Kyung Hee University Hospital Kyung Hee University Hospital Table 5. Multivariate Analysis of Laboratory Data for RT-PCR Positivity in the 3rd Generation Anti-HCV ELISA Positive Patients

Kyung Hee University Hospital Kyung Hee University Hospital Conclusion  The positive predictability of the third generation anti-HCV test was 56.3%  significant difference between the S/CO ratio below 6 (18%) and above 6 (63%)  In liver cirrhosis, positive predictability of anti-HCV test was relatively high as 85%